MedTrace Logo

A RCT to Assess the Performance of CytoSorb for Shock Reversal in Patients With Vasoplegic Septic Shock

NCT04963920 · Status: SUSPENDED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 260

Last updated 2025-08-05

No results posted yet for this study

Summary

To assess the performance of the CytoSorb® 300 mL device for shock reversal in patients with vasoplegic septic shock.

Conditions

  • Septic Shock

Interventions

DEVICE

Cytosorb® 300 ml

patients will receive CytoSorb therapy in addition to standard of care therapy according to applicable guidelines

Sponsors & Collaborators

  • BRAHMS GmbH

    collaborator UNKNOWN

  • MedInnovation GmbH

    collaborator INDUSTRY

  • CytoSorbents Europe GmbH

    lead INDUSTRY

Principal Investigators

  • Stefan Kluge, Prof · Universitätsklinikum Hamburg-Eppendorf (UKE)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-30
Primary Completion
2027-02-28
Completion
2027-05-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04963920 on ClinicalTrials.gov